12月15日 - ** 药物开发商ImmunomeIMNM.O的股票在盘前交易中大涨30.3%，至25.5美元
** 公司称其实验性疗法达到了后期试验的主要目标
** 该公司正在对蝶形细胞瘤进展期患者进行药物varegacestat试验
** 蝶形细胞瘤是结缔组织产生的非癌症肿瘤
** 在试验中，与安慰剂相比，该药物可将疾病进展或死亡风险降低 84
** Varegacestat 一般耐受性良好，安全性可控 - IMNM
** 截至上次收盘，股价累计上涨 84.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.